What Is Tesamorelin?
Tesamorelin is a synthetic analog of human GHRH(1-44). A trans-3-hexenoyl group added to the N-terminus protects the peptide from rapid enzymatic degradation, giving it a longer functional life than native GHRH while preserving the natural signaling sequence.
Because it is a GHRH analog, Tesamorelin acts upstream of growth hormone. It engages the GHRH receptor on the anterior pituitary and stimulates the gland to release its own growth hormone in a pulsatile pattern, which in turn raises insulin-like growth factor 1 (IGF-1). This upstream position is the defining feature of the compound.
Studied Mechanism And Metabolic Effects
In research and clinical literature, Tesamorelin is most associated with reductions in visceral adipose tissue — the metabolically active fat surrounding the internal organs. It was studied and approved specifically for excess visceral fat in the context of HIV-associated lipodystrophy, which makes it one of the better-characterized peptides in this library from a regulatory standpoint.
Because it drives the pituitary to release growth hormone in physiologic pulses rather than delivering a flat exogenous dose, Tesamorelin is often contrasted with direct growth hormone administration in research discussions of how the growth-hormone axis is best studied.
Tesamorelin Versus Growth Hormone Secretagogues
Tesamorelin and the growth hormone secretagogues (GHS) both raise growth hormone, but through different receptors. Tesamorelin is a GHRH-receptor agonist. Secretagogues such as Ipamorelin, GHRP-2, and GHRP-6 act on the ghrelin/GH-secretagogue receptor. The two pathways are complementary in research models, which is why GHRH analogs and GHS are sometimes studied in combination.
- Tesamorelin: GHRH-receptor agonist, stabilized GHRH(1-44) analog.
- Growth hormone secretagogues: ghrelin-receptor agonists (Ipamorelin, CJC-1295, GHRP-2/6).
- Both raise endogenous growth hormone and IGF-1 but through distinct receptor systems.
Research Context And Handling
Tesamorelin research uses endpoints such as growth-hormone and IGF-1 measurement and, in preclinical models, imaging of adipose depots. As with any Research Use Only compound, verified identity and purity from the Certificate of Analysis, appropriate storage, and interpretation against the primary literature are essential. The compound is supplied strictly for laboratory research and not for human or animal use.
Research Use Only: This guide is informational and describes research-context handling of compounds intended strictly for in vitro laboratory research. Products are not for human or animal consumption, ingestion, or injection, and are not FDA-approved. Nothing here is medical, clinical, or dosing advice.
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone, GHRH(1-44). It engages the GHRH receptor on the pituitary to stimulate the body’s own pulsatile growth-hormone release, raising IGF-1.
How is Tesamorelin different from a growth hormone secretagogue?
Tesamorelin is a GHRH-receptor agonist, while secretagogues such as Ipamorelin and GHRP-2 act on the ghrelin/GH-secretagogue receptor. Both raise growth hormone, but through distinct receptor systems.
What is Tesamorelin studied for?
It is most associated in research with reductions in visceral adipose tissue and was studied and approved specifically for excess visceral fat in HIV-associated lipodystrophy. It is a Research Use Only compound for in vitro laboratory research.